Sustained remission of CIDP associated with Evans syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15326255.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A patient with chronic inflammatory demyelinating polyneuropathy (CIDP) developed Evans syndrome (hemolytic anemia/thrombocytopenia) 17 months after onset of symptoms despite different immunomodulatory treatments. A therapeutic approach with the chimeric monoclonal anti-CD20 antibody rituximab induced substantial improvement of CIDP and hematologic recovery. The patient remains in sustained remission 17 months after completion of therapy. Rituximab may represent a successful therapy in otherwise refractory CIDP.
Medical subject headings
- Anemia, Hemolytic, Autoimmune
- Antibodies, Monoclonal
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Purpura, Thrombocytopenic, Idiopathic